Core Diagnostics India to market CardioDx CAD test

Source：CardioDx, Inc. Release Date：2013-04-29 265

Medical Equipment

Exclusive product marketing and sales agreement for Corus? CAD, the only clinically validated gene expression test for the assessment of obstructive coronary artery disease

PALO ALTO, California – CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced it has entered into an agreement granting to Core Diagnostics India the exclusive right to market and sell CardioDx's Corus? CAD diagnostic test in India, for the assessment of patients with signs and symptoms suggestive of obstructive coronary artery disease (CAD).

Corus CAD requires just a simple blood draw to conveniently, safely, and reliably help clinicians evaluate the presence of obstructive CAD in stable non-diabetic patients early in the diagnostic pathway. The noninvasive blood-based gene expression test has the potential to reduce patients' exposure to unnecessary invasive and noninvasive procedures.

Under the agreement, Core Diagnostics will make Corus CAD available to patients in India, which has one of the highest rates of CAD[1] in the world and where over USD15 billion is spent annually on out-of-pocket health care expenses[2]. Blood samples collected from patients in India for Corus CAD testing will be sent overnight to CardioDx's CLIA-certified laboratory in Palo Alto, California, for rapid analysis and turnaround.

"We are very excited about our agreement with Core Diagnostics that will expand the reach of Corus CAD to India and provide those patients with a safe and reliable alternative to traditional imaging and invasive testing methods, which may expose patients to radiation, imaging agent intolerance and other procedure-related risks and complications," said David Levison, president and chief executive officer of CardioDx. "Core Diagnostics is an innovative leader at the forefront of advanced diagnostic testing in India and an ideal marketing partner for CardioDx."

Gurgaon-based Core Diagnostics India offers a comprehensive menu of specialized, advanced diagnostic testing in India in the areas of cardiology, oncology, reproductive disorders, endocrinology and infectious diseases. The company provides patients with peace of mind by delivering second opinions on all cases by at least two specialists from a global panel of pathologists.

"Molecular, genomic and proteomic based diagnostics will play a crucial role in disease stratification, and in objectively selecting the best treatment path," said GurAdidas Falcon